Skip to content
Axe Capital logo Axe Capital Trading News

Axe Capital Investments

Clear market notes built around the JSE, the rand, and what matters locally.

Axe Capital Trading News shares simple market takes on the stories moving South African shares, the rand, and a handful of major currency pairs.

What you will find here:

1. JSE shares, South African companies, and the local knock-on effects of big market news.

2. The rand, interest rates, and a small group of forex pairs, with USD/ZAR at the centre.

3. Global stories only when they can actually change how a local investor might act.

Latest market stories

Why Wall Street Keeps Underestimating Micron
2026-07-31 19:30 The Motley Fool Positive Axe Cap view: Selective

Micron Technology quadrupled its revenue year-over-year and guided to $50 billion in Q4 revenue with 20%+ sequential growth, yet the stock has fallen 27% from all-time highs. Wall Street fears a repeat of fiscal 2023's inventory glut, but the company's new multiyear Strategic Customer Agreements and strong AI infrastructure demand suggest these concerns are overblown. With AI projected to grow at 30.6% CAGR through 2033 and tech giants aggressively expanding data centers, Micron's memory chips remain central to the AI boom.

Axe note: Micron’s strong growth and solid customer contracts clash with fears of a chip glut, creating opportunity.

Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
2026-07-31 19:29 The Motley Fool Positive Axe Cap view: Selective

Abbott Laboratories and Johnson & Johnson are compared as healthcare investments for 2026. Abbott trades at lower valuations with expected 13% sales growth but faces litigation risks and slower growth in key products like FreeStyle Libre. Johnson & Johnson offers superior profitability and a robust pharmaceutical pipeline with 28 billion-dollar products, though it faces talc settlement costs and biosimilar competition. Abbott is recommended as the better buy due to stronger expected sales growth and lower valuation metrics.

Axe note: Abbott’s growth story looks more compelling than J&J’s, despite some risks.

Forget SpaceX's Upcoming Q2 Results. History Says You Should Wait at Least This Long Before Buying SpaceX Stock.
2026-07-31 19:19 The Motley Fool Negative Axe Cap view: Neutral

Historical data suggests investors should wait until mid-2027 or later before buying SpaceX stock, despite the company's recent IPO and operational achievements. Large IPOs typically underperform their market index by 4% over three years, and SpaceX's high P/S ratio of 76 (versus tech sector average of 9) indicates overvaluation. Additionally, accelerating capital expenditures in AI investments raise concerns about future returns.

Axe note: SpaceX’s lofty valuation and IPO history suggest patience is key before jumping in.

What we follow

We keep the focus on JSE shares, the rand, and the currency moves that matter most to South African investors.

JSE and rand